Lyman GH. Venous Thromboembolism in the Patient With Cancer: Focus on Burden of Disease and Benefits of Thromboprophylaxis. Cancer 2011; 117(7):1334-1349. http://onlinelibrary.wiley.com/doi/10.1002/cncr.25714/pdf (accessed 25 January 2015)
Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology 2011; 22(6):85-92.
Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. British Journal of Cancer 2010; 102:s2-s9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315367/ (accessed 23 January 2015)
Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. The Lancet Oncology 2005; 6(6): 401-410.
Streiff MB. Association Between Cancer Types, Cancer Treatments, and Venous Thromboembolism in Medical Oncology Patients. Clinical Advances in Haematology & Oncology 2013; 11(^): 349-357.
Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Annals of Oncology 2005; 16(5):696-701. http://annonc.oxfordjournals.org/content/16/5/696.full (accessed 24 January 2015).
Lee AY, Levine MN. Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation 2003; 107:17-21. http://circ.ahajournals.org/content/107/23_suppl_1/I-17.full.pdf+html (accessed 27 January 2015).
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P,Trent D, Francis CW. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. Journal of Clinical Oncology 2007; 25(34): 5490-5505. http://jco.ascopubs.org/content/25/34/5490.full.pdf+html (accessed 24 January 2015).Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar
AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology 2005; 23(10): 2123-2129.
Noble S, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliative Medicine 2005; 19(3): 197-201
Rhodes S, Bond S. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism. European Journal of Oncology Nursing 2008; 12: 425-429.
Meyer G, Marjanovic A, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Maignan CL, Extra JM, Cottu P, Farge D. Comparison of Low-Molecular-Weight-Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer. JAMA Internal Medicine 2002; 162(15): 1729-1735.